Page 1

EX - 99.1 2 d182516dex991.htm EX - 99.1 Exhibit 99.1 INTRA - CELLULAR THERAPIES REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE CAPLYTA supplemental new drug applications ( sNDAs ) for the treatment of bipolar depression are under review by the FDA , with a PDUFA target action date of December 17 , 2021 . Second quarter CAPLYTA total prescriptions ( TRx ) increased 22 % versus the previous quarter . Total revenues for the second quarter were $ 20.0 million . CAPLYTA achieved net product revenues of $ 19.0 million for the second quarter . Patient enrollment in Study ' 501 , a Phase 3 clinical trial evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder ( MDD ) , has commenced . NEW YORK , August 9 , 2021 / GLOBE NEWSWIRE / — Intra - Cellular Therapies , Inc. ( Nasdaq : ITCI ) , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders , today announced its financial results for the second quarter ended June 30 , 2021 and provided a corporate update . " We are pleased with our strong results in the second quarter . Our sNDAs for bipolar depression are under review by the FDA and our CAPLYTA strategy continues to make substantial progress with our commercialization in schizophrenia , along with our preparations for a potential label expansion into bipolar depression . We have initiated patient enrollment in our Phase 3 program in MDD and continue our programs studying other depressive disorders , " said Dr. Sharon Mates , Chairman and CEO of Intra - Cellular Therapies . Second Quarter Financial Highlights Total revenues were $ 20.0 million for the second quarter of 2021 , compared to $ 1.9 million of total revenues for the second quarter of 2020. Net product revenues of CAPLYTA were $ 19.0 million for the second quarter of 2021 , compared to $ 1.9 million in net product revenues of CAPLYTA for the same period in 2020. Net product revenues of CAPLYTA increased 22 % from $ 15.6 million in the prior quarter .